Information Provided By:
Fly News Breaks for November 7, 2019
Nov 7, 2019 | 06:37 EDT
Barclays analyst Gena Wang lowered her price target for Puma Biotechnology to $6 from $9 and keeps an Underweight rating on the shares. Puma reported Q3 Nerlynx revenue of $53.6M, below the consensus of $59.0M, and lowered its 2019 guidance for the second time to $205M-$210M from $220M-$240M, Wang tells investors in a research note. The analyst continues to see a limited growth outlook in extended adjuvant setting as well as metastatic HER2+ breast cancer.
News For PBYI From the Last 2 Days
There are no results for your query PBYI